Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Given the high mortality associated with infant HIV-1 and the fact that surrogate markers are poorly predictive of mortality risk,empiric highly active antiretroviral therapy (HAART) initiation is started in infants younger than 12 months. A problem with this approach is that it obligates infants to life-long therapy, which may be associated with cumulative drug toxicity, poor adherence, and treatment failure. Early HAART for prevention of mortality during the first 2 years of life has potential to salvage immune function and alter viral set-point, allowing withdrawal of therapy, perhaps for several years, until subsequent CD4% decline requires it. This untested approach is attractive because it combines the survival benefits of early pediatric HAART therapy with the benefits of antiretroviral deferral.

One hundred and fifty infants who initiated HAART at \<13 months of age will be treated with HAART regimen for 24 months after which those who have immune reconstitution and adequate growth (\~100) will be randomized to continued versus deferred therapy. Clinical outcomes, growth, and toxicity will be compared in these children to determine if interruption is a safe and beneficial strategy. Follow-up in this studies will be closely monitored by an external Data Safety and Monitoring Board (DSMB).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya

NCT00427297

HIV Infections

TERMINATED PHASE3

Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV

NCT00016783

HIV Infections

COMPLETED

Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)

NCT02063880

Human Immunodeficiency Virus Immune Reconstitution Inflammatory Syndrome

COMPLETED NA

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

NCT00039741

HIV Infections

COMPLETED PHASE2/PHASE3

Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV

NCT01433185

HIV Infections Acquired Immunodeficiency Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypothesis: Deferring antiretroviral therapy in infants who have immune reconstitution and adequate growth following early therapy of primary infection (initiated HAART during primary infection at less than 13 months of age) will not compromise clinical status or growth and may spare antiretroviral toxicity.

Specific Aim/Primary Objective: To compare growth and morbidity in infants (who initiated HAART during primary infection at less than or equal to 13 months of age with subsequently normalized CD4% and growth following 24 months of HAART) randomized to deferred versus continuous therapy and followed for an additional 18 months.

Secondary Aim/Secondary Objective: To determine predictors of non-progression of HIV among the infants, including: age, adherence, HIV-1 specific immune responses, baseline HIV-1 RNA, CD4 percent and immune activation.

Design: Randomized clinical trial involving HIV-1 treatment of infants (\<13 months old) for 24 months, followed by randomization and 18 months follow-up of children randomized to continued versus deferred treatment. This trial is unblinded.

Population: HIV-1 infected infants (\<13 months) newly initiating HAART and HIV-1 infected infants already receiving HAART who initiated HAART at age \<13 months will be enrolled. After 24 months of treatment follow-up, children with CD4% \> 25% and normalized growth will be retained in the study and randomized.

Sample size: 150 infants will be enrolled of which 100 are expected to be eligible for randomization (50 in each arm).

Treatment: All infants will be treated with HAART according to WHO and Kenyan national guidelines. The specific regimens that will be used as a part of this study are:

First line regimen

* AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)
* d4T/3TC/NVP (stavudine/lamivudine/nevirapine)
* AZT/3TC/ABC (zidovudine/lamivudine/abacavir)
* d4T/3TC/ABC (stavudine/lamivudine/abacavir)
* ABC/3TC/NVP (abacavir/lamivudine/nevirapine)

Second line regimen - ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (Kaletra))

For infants with prior exposure to nevirapine as part of PMTCT:

First line regimen

\- AZT/3TC/LPV/r (zidovudine/lamivudine/lopinavir-ritonavir (kaletra))

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interrupted HAART

After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.

Group Type NO_INTERVENTION

No interventions assigned to this group

Continued HAART

After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.

Group Type ACTIVE_COMPARATOR

HAART

Intervention Type DRUG

Combination first line antiretrovirals as previously described.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HAART

Combination first line antiretrovirals as previously described.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A. Infants newly initiating HAART

* Less than 13 months of age
* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
* Caregiver of infant plans to reside in Nairobi for at least 3 years (reported by caregiver)
* Caregiver is able to provide sufficient location information

B. Infants already receiving HAART

* Initiated HAART at \<13 months of age
* Records confirming HIV positive status
* Documentation of CD4% and weight prior to HAART initiation
* Must be on 1st line drug regimen

Eligibility for randomization:

* Completed 24 months of treatment with HAART
* Normalized growth: weight for height z-score (WHZ) \> -0.5; Child's weight must be above the 5th weight-for-age percentile and the weight curve must not be flat or falling (i.e. cross 2 major percentile lines or more over the past 3 months)
* CD4% \> 25
* Children who recently initiated or who require anti-tuberculosis treatment at the time of randomization will be ineligible for randomization.

Maximum Eligible Age

54 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No